[The first experience of using membranotropic agents in the treatment of the nephrotic syndrome]
Related Experiment Videos
Insights
Two membrano-stabilizing agents, zaditen and dimephosphon, show promise for treating childhood nephrotic syndrome. Zaditen reduced activity in hormone-resistant cases, while dimephosphon decreased proteinuria and improved immune markers in some children.
Area of Science:
- Pediatric Nephrology
- Pharmacology
Background:
- Nephrotic syndrome in children presents challenges in treatment, with distinct forms including hormone-dependent and hormone-resistant types.
- Identifying specific patient profiles, such as atopy or cellular membrane instability, is crucial for guiding therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of membrano-stabilizing agents, zaditen and dimephosphon, in treating childhood nephrotic syndrome.
- To explore the differentiated application of these agents based on clinical and immunological characteristics of the disease.
Main Methods:
- Administration of zaditen, an antiallergic and membrano-stabilizing agent.
- Administration of dimephosphon, a membrano-stabilizer and immunomodulator.
- Patient stratification based on examination data, including signs of atopy, cellular membrane instability, and immunological deviations.
Main Results:
- Zaditen treatment led to a significant decrease in disease activity in most children with hormone-resistant nephrotic syndrome.
- In some cases, including hormone-dependent nephrotic syndrome, zaditen allowed for a reduction in prednisolone dosage.
- Dimephosphon treatment resulted in reduced proteinuria, improved cellular membrane stability, and enhanced immunological parameters in a subset of children with hormone-resistant nephrotic syndrome.
Conclusions:
- Membrano-stabilizing agents like zaditen and dimephosphon offer potential therapeutic benefits in managing childhood nephrotic syndrome.
- Differentiated drug application based on specific patient characteristics can optimize treatment outcomes.
- Further research into these agents may lead to improved management strategies for pediatric nephrotic syndrome.
Abstract:
To treat children suffering from the nephrotic syndrome, use was made of the membrano-stabilizing agents: zaditen that also has an antiallergic action; dimephosphon, a membrano-stabilizer and immunomodulator. The basis for differentiated use of the drugs was formed by the examination data which enabled one to identify the signs of atopy in children with the hormone-dependent nephrotic syndrome, marked signs of the instability of cellular membranes and different immunologic deviations in children with the hormone-resistant variety of the nephrotic syndrome. During zaditen treatment, the majority of the children with the hormone-resistant nephrotic syndrome manifested an appreciable decrease of the process activity; in some cases, including those with hormone dependence, the treatment with prednisolone could be reduced. In part of the children with the hormone-resistant nephrotic syndrome, the treatment with dimephosphone resulted in a decrease of proteinuria, reduced the instability of cellular membranes, and improved the immunologic parameters.